Bright Minds Biosciences (TSE:DRUG)
:DRUG
Want to see TSE:DRUG full AI Analyst Report?
DRUG Stock Chart & Stats
C$123.50
C$0.00(0.00%)
At close: 4:00 PM EST
C$123.50
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$33.01 - C$170.00
Previous CloseN/A
Volume70.00
Average Volume (3M)451.00
Market Cap
C$1.21B
Enterprise ValueC$644.54M
Total Cash (Recent Filing)C$308.68M
Total Debt (Recent Filing)C$81.86K
Price to Earnings (P/E)―
Beta22.14
Next Earnings
Aug 13, 2026EPS Estimate
-1.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding9,787,161
10 Day Avg. Volume620
30 Day Avg. Volume451
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.07
Price to Sales (P/S)0.00
P/FCF Ratio-66.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$227.56Price Target Upside84.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and sizable equity provide durable financial flexibility for a development-stage biotech. This reduces near-term refinancing risk, supports sustained R&D spending or strategic partnerships, and gives management optionality to fund programs without immediate distressed capital raises.
Focused Clinical-stage PipelineA concentrated scientific focus on 5-HT receptor pharmacology creates structural expertise and a differentiated R&D strategy. This can improve trial design, deepen domain knowledge, and make the company a more attractive partner or acquisition target if clinical signals validate the approach.
Cash Burn Aligns With Net LossesFree cash flow tracking net income indicates losses are driven by real cash R&D and operating spend rather than large non-cash charges. That predictability aids budgeting, cash-runway modeling and makes funding needs more transparent for investors and potential partners.
Bears Say
Pre-revenue And Widening LossesAbsence of commercial revenue means the company relies on financing or deals to sustain operations. Widening losses increase funding frequency and dilution risk, and delay any path to operating leverage, heightening execution risk until clinical progress translates into partnerships or revenue.
Elevated Cash BurnRising cash burn raises the probability the company must raise capital within months to fund R&D. Even with a strong balance sheet today, persistent higher spend accelerates runway exhaustion, can force dilutive financings, or compel early partnering under less favorable terms.
Negative ROE / No MarginsNegative ROE and absent margins indicate capital deployed is not generating returns and shareholders face prolonged value creation uncertainty. Without commercialization or licensing revenue, it is difficult to achieve positive operating leverage, which may limit long-term capital efficiency.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was C$33.01 and its highest was C$170.00 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is C$1.21B.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Aug 13, 2026 which is in 75 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on May 19, 2026. The company reported -C$1.09 earnings per share for the quarter, beating the consensus estimate of -C$1.185 by C$0.095.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.74.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,787,161 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -C$1.09 in its last earnings report, beating expectations of -C$1.185. Following the earnings report the stock price went up 7.847%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in TSE:DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bright Minds Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$227.56 (84.26% Upside)
C$227.56 (84.26% Upside)
Blogger Sentiment
Bullish
TSE:DRUG Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth C$13.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
145.60%
12-Months-Change
Fundamentals
Return on Equity
-20.73%
Trailing 12-Months
Asset Growth
453.16%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
DRUG Stock 12 Month Forecast
Average Price Target
C$227.56
▲(84.26% Upside)
Technical Analysis
―
Entheon Biomedical
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Options Prices
Currently, No data available
---